RxDoctor Payments Data

Aimee Garza, MD

Neurology · Frisco, TXNPI 1487854667

Payments from drug & device makers

$436,171in general payments, 2019–2025

Across 2,318 payments — averaging $188.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$235K
  • AbbVie$58K
  • Teva Pharmaceuticals USA, Inc.$46K
  • Impel Pharmaceuticals Inc.$18K
  • Axsome Therapeutics, Inc.$16K
  • SK Life Science, Inc.$7K
  • plus $54K from 54 others

What the payments were for

  • Consulting fees$32,91116%
  • Speaking & faculty fees$120,65460%
  • Travel & lodging$5,1583%
  • Food & beverage$42,10721%
  • Education$3830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly2$234,957
AbbVie(2 entities)440$58,345
Teva Pharmaceuticals USA, Inc.108$46,430
Impel Pharmaceuticals Inc.22$17,525
Axsome Therapeutics, Inc.45$16,199
SK Life Science, Inc.44$7,418
Novartis89$6,348
Biohaven Pharmaceuticals, Inc.57$5,932
Banner Life Sciences, LLC13$5,041
Lundbeck LLC69$4,102
EMD Serono, Inc.73$3,453
Biohaven Pharmaceutical Holding Company Ltd.79$3,116
Biogen120$2,792
Livanova USA, Inc.15$1,791
UCB, Inc.64$1,436
Genentech USA, Inc.46$1,220
Neurocrine Biosciences, Inc.44$1,124
Supernus Pharmaceuticals, Inc.68$1,097
Amgen(2 entities)54$1,067
Sanofi44$1,066
Lilly USA, LLC55$998
Pfizer89$855
Eisai Inc.32$788
Argenx US, Inc.23$775
Upsher-smith Laboratories LLC35$716
Acadia Pharmaceuticals Inc36$693
EDW Pharma, Inc.2$593
Bristol Myers Squibb29$540
Tanabe Pharma America, Inc.34$531
Avanir Pharmaceuticals, Inc.78$486
Grifols USA, LLC22$480
Neurelis, Inc.11$422
Johnson & Johnson(2 entities)54$367
AstraZeneca(2 entities)17$365
CSL Behring14$360
MDD US Operations, LLC9$356
Jazz Pharmaceuticals Inc.17$352
Scilex Pharmaceuticals Inc.10$341
Amneal Pharmaceuticals LLC17$339
Acorda Therapeutics, Inc15$328
Adamas Pharmaceuticals, Inc.16$324
Abbott11$246
Otsuka America Pharmaceutical, Inc.12$244
Alnylam Pharmaceuticals Inc.12$233
Kyowa Kirin, Inc.11$232
Merz Pharmaceuticals, LLC8$212
Merz North America, Inc.6$186
Harmony Biosciences LLC11$182
Assertio Therapeutics, Inc.12$182
Takeda Pharmaceuticals U.S.A., Inc.8$179
Impel Pharmaceuticals LLC8$166
Springworks Therapeutics, Inc.4$160
E.r. Squibb & Sons, L.L.C.3$141
Sunovion Pharmaceuticals Inc.9$139
Novo Nordisk1$124
Penumbra, Inc.1$121
Idorsia Pharmaceuticals US Inc1$119
Tonix Medicines, Inc.3$118
Corium, LLC5$104
Cycle Pharmaceuticals Inc3$103

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$436,171 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$47,117
Medicare patients
123
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a27$216,269
IngrezzaValbenazine Tosylate19$149,632
BotoxOnabotulinumtoxina97$113,451
Nurtec OdtRimegepant Sulfate68$100,344
NuplazidPimavanserin Tartrate18$89,127
QuliptaAtogepant41$64,017
UbrelvyUbrogepant41$61,596
Aimovig AutoinjectorErenumab-Aooe47$46,126
Emgality PenGalcanezumab-Gnlm63$45,508
BriviactBrivaracetam21$29,173
FingolimodFingolimod Hcl15$27,862
Ajovy AutoinjectorFremanezumab-Vfrm19$17,483
NeuproRotigotine16$14,755
BelsomraSuvorexant21$9,955
Carbamazepine ErCarbamazepine32$5,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$58,345$239,064179 claims
Neurocrine Biosciences, Inc.Ingrezza$1,124$149,63219 claims
PfizerNurtec Odt$855$100,34468 claims
Acadia Pharmaceuticals IncNuplazid$693$89,12718 claims
UCB, Inc.Briviact, Neupro$1,436$43,92837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →